Trastuzumab’s US launch will be a big opportunity for Biocon-Mylan: Shaw

Kiran Sidandia, managing director and COO of Biocon, said the company is ready to launch trastuzumab in the US market. (Photo: Mint)

Over the last two decades, the US market has been a sweet spot for the Indian pharma industry. Indian companies have been trying to expand their footprint in the US, but the competition and regulatory hurdles are considerable.

What are your views on what happened in the US pharma market in 2018 and what are your views on it? What are the hopes and fears for 2019? What are the biggest challenges that the US market poses for Indian companies in terms of regulatory and distribution challenges? How do you see the US market for Indian companies?

There are many reasons why the US market is attractive to Indian companies. First, it is one of the largest markets for pharmaceuticals globally. Second, it is a mature market with a well-established healthcare system. Third, it is a market with high growth potential, particularly in the area of specialty drugs.

The US market is also attractive because of its high profitability. It is estimated that the US market contributes more than 50% of the revenue of many Indian pharmaceutical companies. The US market is also important because it is a market with a high degree of innovation, and it is a market where many of the new drugs are first tested.

However, the US market is also challenging. It is a highly regulated market with strict regulations on drug development, marketing, and reimbursement. The US market is also a highly competitive market with many established players.

Despite the challenges, Indian companies are making significant investments in the US market. They are setting up R&D facilities, establishing distribution networks, and developing new products. Many Indian companies are also expanding into other markets in order to spread their risk.

The US market is a complex market, and it is important for Indian companies to have a clear understanding of the market before they enter it. They need to have a strong understanding of the regulatory landscape, the reimbursement system, and the competitive landscape.

Nevertheless, the US market is a valuable market for Indian companies. It is a market with high growth potential and high profitability. Indian companies are making significant investments in the US market, and they are likely to continue to do so in the future.